Pharma AI Tracker

Galderma says its lead for Automation and AI has been building Galderma's AI Framework and establishing an AI Center of Excellence. The article quotes him saying predictive and generative AI are helping the company accelerate research and development, anticipate trends, personalize experiences and drive digital transformation.

Galderma says tech teams at its Uppsala manufacturing and R&D facility are using a custom-built AI interface to analyze handwritten documents, so that 30 years of historical R&D data can support new experiments and new products.

Takeda's Japan manufacturing and supply unit brought in an AI demand-forecasting model for production planning. It replaces a mostly history-and-expert approach.

Amgen adopted OpenAI's ChatGPT Enterprise early and widened access across the company in phases, with security controls.

Partners: OpenAI

AstraZeneca built Development Assistant on AWS, a multi-agent tool that lets development teams ask plain-language questions of their data and get answers quickly.

Partners: AWS

An enterprise rollout of Microsoft Copilot starting in early 2024 that reached about 20,000 employees. Users saved about 2.17 hours a week on average.

Partners: Microsoft

Incyte's 2024 global responsibility report says that on Rare Disease Day the company launched The Unseen Journey, using generative artificial intelligence to illustrate the experiences of people living with myeloproliferative neoplasms. It says that as patients described their symptoms, generative AI created images of the hidden emotional and physical toll of those diseases, and that the stories and images were shared through 2024.

Merck built an internal generative AI tool that drafts clinical study reports for human review, more than halving first-draft effort, and has submitted CSRs produced this way.

A generative AI tool that helps write Sanofi's annual product quality reviews (PQRs). In June 2025 Sanofi reported about 3,500 PQRs a year and a target to cut creation time by 70 percent. An Aug 2024 Outsourced Pharma interview with Sanofi reported PQR writing about eightfold faster, a reported result and not a target.

Amgen process development staff use generative AI tools over a curated technical knowledge base of more than a million documents, with evaluations and risk-based validation.

In 2024, Viatris implemented emerging technology and artificial intelligence to improve adherence to compliance policy requirements by launching a new tool. The report describes that tool as chatbot-style policy search.

During 2024, Viatris continued exploring emerging technologies, including artificial intelligence, to potentially enhance product safety evaluation, communication and risk mitigation.

A strategy scorecard in Torrent's 2024-25 integrated report lists implementing AI tools for quality management systems.

Torrent's 2024-25 integrated report says the company is evaluating AI tools to optimise various regulatory and quality-related activities, with the stated aim of faster decision-making and improved compliance management.

Takeda chose Salesforce's AI-enabled Life Sciences Cloud to give commercial teams embedded insights for engaging healthcare professionals.

Partners: Salesforce

PharmaEssentia's 2024 annual report says its U.S. subsidiary continued to extend the drug's reach through AI technologies, together with social media, advocacy groups, clinic information displays and dedicated websites.

The PharmaEssentia Innovation Research Center site says its data science team uses an extensive database and employs AI and ML to select checkpoint-receptor targets. The same page says the center uses AI and machine learning to establish databases so it can select novel targets and patients more wisely and screen molecules faster.

In a talk summarised by OMP, J&J described its next-generation supply planning tool, including an AI assistant that surfaces insights for planners in real time.

Partners: OMP

Amgen's knowledge management team built a Q&A agent in Copilot Studio that searches the company's large body of R&D documents and reports.

Partners: Microsoft

Astellas says it has been integrating AI into drug development since 2019 and that its Human-in-the-Loop platform, which combines human expertise, AI and robotics, is widely used in small- and medium-molecule discovery. The article says that by leveraging AI, employees have cut the time to refine a hit compound into a drug candidate by approximately 70% compared with traditional methods.

The same report lists, as a high-value J&J AI use case, an internal chatbot for employees that answers questions on company policies and benefits.

Citing the Wall Street Journal, PYMNTS reports that one of J&J's highest-value AI uses is a generative AI copilot that coaches reps on engaging healthcare professionals.

Amgen's ATOMIC tool ranks candidate trial sites with machine learning, and Amgen reports that top-ranked sites enrolled patients markedly faster.

Sobi's 2024 annual and sustainability report says the DLBCL, ITP and PNH patient councils co-created AI-driven social media campaigns to empower patients and promote shared decision-making with healthcare professionals.

Astellas and YASKAWA Electric signed an agreement to establish a joint venture that will develop a cell-therapy manufacturing platform using the Maholo robot. The planned business includes optimizing the digitized manufacturing process with AI and building a platform that meets GMP conditions. Establishment was subject to closing conditions, including regulatory approvals.

Partners: YASKAWA Electric Corporation